Fig 2: Characteristics of DYNLT3 and P4HA3. a, e The expression of DYNLT3 or P4HA3 in pre-menopausal normal (blue), post-menopausal normal (red), and tumor (green) samples in TCGA dataset. b, f The expression of DYNLT3 or P4HA3 in normal tissues in the GTEx dataset. c, g The paired comparison of DYNLT3 or P4HA3 between matched tumors and normal tissues in TCGA dataset. d, h The predictive power of DYNLT3 or P4HA3 for relapse-free survival of all and different subtypes of breast cancer patients

Fig 3: Effects of DYNLT3 on the tumor growth and metastasis in a mouse model. (A): DYNLT3 inhibited the tumor growth in nude mice bearing human SiHa cervical cancer cells. Tumor sizes are shown. Numbers: tumor sample numbers. (B): Tumor volumes are presented in mice bearing SiHa cells after DYNLT3 modulation. (C): Downregulation of DYNLT3 promoted the lung metastasis in mice bearing human SiHa cervical cancer cells. (D): HE staining was performed in lung tissues from nude mice bearing SiHa cells after DYNLT3 modulation.

Fig 4: Knockdown of P4HA3 but not DYNLT3 significantly reduced malignancy of BT-474 cell in vivo. Comparison of tumor volume over time (a, d), final tumor weight (b, e), and total flux from luciferase activity in the lungs (c, f) between control and DYNLT3 or P4HA3 knockdown BT-474 cell-inoculated mice. Data are presented as the mean ± sem of ten tumors. Two-sample t tests were used to analyze the data.*P < 0.05; **P < 0.005

Fig 5: Effects of DYNLT3 on the caspase-3 expression in cervical cancer cells. (A, B): Western blotting was performed to measure the expression of caspase-3 and cleaved caspase-3 in SiHa cells (A) and CaSki cells (B) after DYNLT3 modulation.